β-Blockers Myocardial Infarction: Reevaluating ...

By HEOR Staff Writer

January 14, 2026

β-blockers after myocardial infarction in patients with preserved ejection fraction (LVEF ≥50%) do not significantly improve key outcomes like mortality or recurrent events. This addresses a common query: How effective are β-blockers in post-heart...
Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays
Driving Economic Transformation through Brain Health Investment in Africa
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Thro...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards
mRNA Vaccine Advancements: Transforming Infectious Disease Prevention and Equity
Positive ARTISTRY-2 Trial Results for BIC LEN HIV Regimen
Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Pat...
CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals
AKEEGA BRCA2 Approval: Landmark FDA Decision for Precision Therapy in Aggress...
Arexvy RSV Vaccine Expansion: Broader Access and Impact on Adult Health Outcomes